A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
This study is testing an experimental medication called marlotamig, both by itself and combined with other cancer treatments like cemiplimab and chemotherapy. Researchers want to find the safest and most effective doses to help shrink advanced solid tumors.
You might be able to join if you have a confirmed advanced cancer diagnosis, are able to carry out light daily activities, and meet specific treatment history requirements. Your doctors will also need to check that you have a measurable area of cancer and are willing to provide a new tumor tissue sample.
Participants will receive the study medications and be closely monitored for side effects and how the drugs work in the body. This involves regular health checks, blood tests, and tracking how your tumor responds to the treatment.
The study has locations in places like Los Angeles and San Francisco, California. It is currently active, which means ongoing care is happening for enrolled participants, though it is not actively looking for new patients right now.
- 1Tests the new drug marlotamig alone and with other cancer therapies
- 2Focuses on finding the right dose and checking for side effects
- 3Currently active but not recruiting new participants
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.